KVANTO-PAYMENT-SOLUTIONS
6.2.2020 09:02:10 CET | Business Wire | Press release
For Pure Health inc. (FPH) has signed a partnership agreement with Kvanto Payment Services A/S (hereafter Kvanto). FPH provides sales all over the globe. All numbers and assumptions are based on previous first-hand experience with similar setups and products. And has made it before and they have entered with Kvanto and using the Payment Gateway, this has a large opportunity.
“FPH was looking for a partner to handle payments solution. One of the most important things for FPH is that customers experience has a smooth and secure checkout when buying our products from our website.
Kvanto Payment services not only provided us with this solution but also helped us set up the system, quickly and seamlessly. Furthermore, FPH has trusted Kvanto Payment Services with helping FPH with administration, technical, and development.
This special cooperation we have not been able to find elsewhere. From the start of this cooperation, we have made this as a focus development case, and we are now moving it to a slot of large opportunities of 250M € turnover a year and our aim is larger, and Kvanto stands the challenge and we have been satisfying so fare.
Allan Djurhuus
CEO, FPH Inc
.”
Benefits compared to other solution partners
Kvanto has an MPI security Solution, it works outside Europe, and that’s where we have most of the clients in FPH. Kvanto makes sure the merchant’s customer and the cardholder are the same person by sending a code to the customer's cell phone, which the customer must fill into the payment window before the payment is approved.
FPH has made this happen, through our marketing corporation with Konnektive CRM in US/PR and we have worked with Konnektive CRM for years now, and it has been a huge success, and we are so delighted to manage to get both Kvanto and Konnektive CRM together, and we have now one solution, and that saves us a large amount of time and money, we can´s understand why people not are managing this as it has to be, and as Konnektive is saying.
“Time is money.
With hundreds of integrations through Konnektive, you’ll never be scrambling to find your data by going to multiple systems. We put everything you need at your fingertips; all in one place!
Konnektive CRM was designed to Automate
and Synchronize
Your Entire Business with the easiest, most intuitive user interface.
Brian Bolerjack,
Konnektive CRM”
Kvanto cooperation with both the system provider and customer
Kvanto has made an option and an opportunity by creating this cooperation, to manage a whole platform, by offering the Kvanto ESB Payment Gateway, and support the individual customer and the whole group of Konnektive CRM platform solution, as a trusted partner. Kvanto has proved to be highlighted as a service provider that can handle payment transactions across the payment ECO-system, and even if you are making the payment happen in Europe or elsewhere, we can carry the solution to a new level of security by Kvanto MPI solution.
Value proposition
By managing this, and through the Kvanto Gateway Solution, it will be possible to draw more potential clients into our merchants, and our expectation of this cooperation is more than 12 Mill $ in turnover a year, on this case alone.
And the options for new clients is much higher, and we can multiply this 3-4 times.
This is an optimizing way of creating new clients, and we have today two new clients, that bring more merchants in through this cooperation, and we expect to reach some 15-22 clients with the support we have from Konnektive CRM staff and PR from FPH.
About Kvanto Payment Solutions
Kvanto is a Payment Solution Provider company that provides simple, flexible, and cost-efficient payment solutions on the global market. Through experience and knowledge does Kvanto challenge current structures and procedures in the established market.
Kvanto strives to be a one-stop-shop for payments with cross border solutions for merchants and the leading EMEA/APAC multi-connectivity payment solutions provider measured in processing volume while being profitable.
For further investor enquires
Listing Partners LLC
support@listingpartners.lu
All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Kvanto Payment Systems A/S is under no obligation to (and expressly disclaim any such obligation to) update or alters our forward-looking statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005045/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
